NOTCH pathway inactivation promotes bladder cancer progression

Antonio Maraver(Inserm), Pablo J. Fernández-Marcos(Universitat Pompeu Fabra), Timothy P. Cash(Universitat Pompeu Fabra), Marinela Méndez‐Pertuz(Universitat Pompeu Fabra), Marta Dueñas(Universitat Pompeu Fabra), Paolo Maietta(Universitat Pompeu Fabra), Paola Martinelli(Universitat Pompeu Fabra), Maribel Muñoz‐Martín(Universitat Pompeu Fabra), Mónica Martínez‐Fernández(Universitat Pompeu Fabra), Marta Cañamero(Universitat Pompeu Fabra), Giovanna Roncador(Universitat Pompeu Fabra), Jorge L. Martı́nez-Torrecuadrada(Universitat Pompeu Fabra), Dimitrios Grivas(Universitat Pompeu Fabra), José Luís de la Pompa(Universitat Pompeu Fabra), Alfonso Valencia(Universitat Pompeu Fabra), Jesús M. Paramio(Universitat Pompeu Fabra), Francisco X. Real(Universitat Pompeu Fabra), Manuel Serrano(Universitat Pompeu Fabra)
Journal of Clinical Investigation
January 8, 2015
Cited by 120Open Access
Full Text

Abstract

NOTCH signaling suppresses tumor growth and proliferation in several types of stratified epithelia. Here, we show that missense mutations in NOTCH1 and NOTCH2 found in human bladder cancers result in loss of function. In murine models, genetic ablation of the NOTCH pathway accelerated bladder tumorigenesis and promoted the formation of squamous cell carcinomas, with areas of mesenchymal features. Using bladder cancer cells, we determined that the NOTCH pathway stabilizes the epithelial phenotype through its effector HES1 and, consequently, loss of NOTCH activity favors the process of epithelial-mesenchymal transition. Evaluation of human bladder cancer samples revealed that tumors with low levels of HES1 present mesenchymal features and are more aggressive. Together, our results indicate that NOTCH serves as a tumor suppressor in the bladder and that loss of this pathway promotes mesenchymal and invasive features.


Related Papers

No related papers found

Powered by citation graph analysis